PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19569222-6	2010	A Pluronic F108 treated surface is highly resistant to nonspecific protein adsorption under the optimized conditions (MW of 15 k and PEO/PPO ratio of 80/20).	FS-108	11-15	protoporphyrinogen oxidase	Homo sapiens	137-140
11426386-2	2001	Various ratios of end-group-activated tri-block copolymer Pluronic F108 were used to immobilize the extracellular matrix protein fibronectin (FN).	FS-108	67-71	fibronectin 1	Homo sapiens	129-140
12182554-10	2002	Results obtained with F108 coated particles of different sizes showed that particle size had a significant effect on the fibrinogen uptake, with larger particles showing larger fibrinogen uptakes.	FS-108	22-26	fibrinogen beta chain	Homo sapiens	121-131
11426386-2	2001	Various ratios of end-group-activated tri-block copolymer Pluronic F108 were used to immobilize the extracellular matrix protein fibronectin (FN).	FS-108	67-71	fibronectin 1	Homo sapiens	142-144
11426595-3	2001	In this study, we have investigated a technique for covalently immobilizing fibronectin to the PEO-containing triblock copolymer Pluronic F108 ("F108").	FS-108	138-142	fibronectin 1	Homo sapiens	76-87
35192728-4	2022	Together with extended tumor exposure to therapeutically effective drug levels via reversible conjugation to Pluronic F-108 (PF108), these features translated into rapid tumor regression and long-term survival in models of both ABCG2-overexpressing and p53-mutant high-risk neuroblastomas, in contrast to a marginal effect of the clinically used camptothecin derivative, irinotecan.	FS-108	118-123	tumor protein p53	Homo sapiens	253-256